Back to Research Hub
Vaxcyte, Inc.
PCVX
$58.21-1.62 (-2.71%)
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases.
StreetsValue research for Vaxcyte, Inc. (PCVX)
Members get the full report for Vaxcyte, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.